ARTES Biotechnology announced the collaboration with Midas Pharma for strategic marketing opportunities. Aim of the cooperation is the finding of suitable partners for defined pharmaceuticals projects like vaccine and pharmaceutical target development or transfer of Biosimilar processes.
ARTES is specialized in microbial cell line and process development as well as in technology transfer for pharmaceutical industry whereas Midas is an independent marketing and distribution company, which supports clients in finding potential partners and markets.
“We are confident, that we could, together with Midas’ worldwide representatives, break into new markets. Especially our vaccine development platform Metavax® has strong capabilities. The Metavax® platform is suitable for the development and production of cost-effective vaccines and therefore interesting for markets where price is an issue”, Dr. Melanie Piontek, Business Development Director of ARTES pointed out. “The highly expanded network of Midas will open for us new opportunities currently in regions where we not yet in. We are very pleased that, with Midas, we have been able to acquire a very competent and reliable partner.”
ARTES is specialized in microbial cell line and process development as well as in technology transfer for pharmaceutical industry whereas Midas is an independent marketing and distribution company, which supports clients in finding potential partners and markets.
“We are confident, that we could, together with Midas’ worldwide representatives, break into new markets. Especially our vaccine development platform Metavax® has strong capabilities. The Metavax® platform is suitable for the development and production of cost-effective vaccines and therefore interesting for markets where price is an issue”, Dr. Melanie Piontek, Business Development Director of ARTES pointed out. “The highly expanded network of Midas will open for us new opportunities currently in regions where we not yet in. We are very pleased that, with Midas, we have been able to acquire a very competent and reliable partner.”
